May 7, 2026 08:02AM
May 7, 2026 08:01AM
Apr 27, 2026 08:01AM
Mar 9, 2026 04:05PM
Feb 19, 2026 04:01PM
Feb 3, 2026 08:29AM
Feb 3, 2026 08:29AM Ardelyx Receives New Patent for Tenapanor
Jan 23, 2026 12:56PM
Jan 9, 2026 03:20AM
Nov 7, 2025 04:05PM
Nov 7, 2025 04:05PM
Oct 30, 2025 04:01PM
Oct 28, 2025 08:02AM
Oct 28, 2025 08:01AM Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting
Oct 21, 2025 08:00AM
May 6, 2025 08:02AM
May 6, 2025 08:01AM
Apr 24, 2025 08:01AM
Apr 10, 2025 04:03PM
Apr 10, 2025 04:02PM
Mar 31, 2025 04:04PM Ardelyx (ARDX) to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
Mar 31, 2025 04:03PM
Feb 20, 2025 07:30AM
Nov 8, 2024 12:34PM
Nov 8, 2024 12:31PM
Nov 8, 2024 12:31PM
Oct 24, 2024 04:06PM
Oct 24, 2024 04:05PM Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week
Oct 15, 2024 08:00AM
Oct 9, 2024 08:05AM
Oct 9, 2024 08:05AM
Jul 31, 2024 08:02AM
Jul 17, 2024 05:10PM
May 21, 2024 08:02AM
May 16, 2024 08:01AM Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
May 7, 2024 08:01AM
May 2, 2024 04:02PM
May 1, 2024 08:00AM
Feb 22, 2024 04:01PM
Jan 8, 2024 08:05AM
Jan 8, 2024 08:00AM
Jan 3, 2024 08:03AM Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
Nov 15, 2023 04:02PM
Nov 15, 2023 04:02PM
Nov 13, 2023 04:03PM
Nov 13, 2023 04:02PM
Nov 6, 2023 08:02AM
Nov 6, 2023 08:00AM
Nov 3, 2023 08:00AM Ardelyx (ARDX) Reports Positive Data from Studies of XPHOZAH
Nov 3, 2023 08:00AM

322,940 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All